Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma
- 479 Downloads
Hepatocellular carcinoma (HCC) is increasing in incidence and the majority of patients are not candidates for radical therapies. Therefore, interest in minimally invasive therapies in growing.
A Phase I dose escalation trial was conducted at Indiana University to determine the feasibility and toxicity of stereotactic body radiation therapy (SBRT) for primary HCC. Eligible patients had Child-Turcotte-Pugh’s Class (CTP) A or B, were not candidates for resection, had 1–3 lesions and cumulative tumour diameter less than or equal to 6 cm. Dose escalation started at 36 Gy in 3 fractions (12 Gy/fraction) with a subsequent planned escalation of 2 Gy/fraction/level. Dose-limiting toxicity (DLT) was defined as Common Terminology Criteria for Adverse Events v3.0 grade 3 or greater toxicity.
Seventeen patients with 25 lesions were enrolled. Dose was escalated to 48 Gy (16 Gy/fraction) in CTP-A patients without DLT. Two patients with CPC-B disease developed grade 3 hepatic toxicity at the 42-Gy (14 Gy/fraction) level. The protocol was amended for subsequent CTP-B patients to receive a regimen of 5 fractions starting at 40 Gy (8 Gy/fraction) with one patient experiencing progressive liver failure. Four additional patients were enrolled (one died of unrelated causes after an incomplete SBRT course) without DLT. The only factor related to more than one grade 3 or greater liver toxicity or death within 6 months was the CTP score (p=0.03). Six patients underwent a liver transplant. Ten patients are alive without progression with a median FU of 24 months (10–42 months), with local control/stabilisation of the disease of 100%. One and two-year Kaplan-Meier estimates for overall survival are 75% and 60%, respectively.
SBRT is a non-invasive feasible and well tolerated therapy in adequately selected patients with HCC. The preliminary local control and survival are encouraging. A confirmatory Phase II trial is currently open to accrual.
KeywordsHepatocellular carcinoma Stereotactic body radiotherapy
Unable to display preview. Download preview PDF.
- 3.American Cancer Society (2009) Cancer facts and figures. American Cancer SocietyGoogle Scholar
- 7.Lui L (2002) Radiofrequency ablation of liver cancers. World J Gastroenterol 8:392–399Google Scholar
- 15.Mornex F, Girard N, Beziat C et al (2006) Feasibility and efficacy of high-dose three-dimensionalconformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies: mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys 66:1152–1158PubMedGoogle Scholar
- 20.Kelsey CR, Schefter T, Nash SR (2003) Retrospective clinicopathologic correlation of gross tumor size of hepatocellular carcinoma: implications for extracranial stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 57:S283Google Scholar
- 22.Cancer Therapy Evaluation Program Website: ctep.cancer.gov/forms/CTCAEv3.pdfGoogle Scholar
- 25.Henderson MA, Azzouz F, Breen T (2007) Preliminary toxicity analysis of phase I/II trial evaluating stereotactic body radiotherapy for the treatment of hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 69:S297 [Abstract]Google Scholar
- 27.ICRU (1999) Report 62: prescribing, recording and reporting photon beam therapy (supplement to ICRU Report 50). International Commission on Radiation Units and Measurements, BethesdaGoogle Scholar
- 28.Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada [see comment]. J Natl Cancer Inst 92:205–216CrossRefPubMedGoogle Scholar
- 31.Timmerman R, McGarry R, Papiez L (2005) Initial report of a prospective phase II trial of stereotactic body radiation therapy for patients with medically inoperable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 63:S99Google Scholar